Start 30 days free, no card. Full Pro access for a month, then decide. Start free
Analyst
Mike Sison
Period: Reporting periods mapped to calendar 2024 Q3 – 2026 Q1 (7 quarters).
- Questions
- 54on tracked calls
- Challenge rate
- 19%10 of 54 questions
- Companies
- 11questioned at least once
- Reporting periods
- 7with questions
These figures cover the whole profile: every tracked question, all reporting periods.
How to read these numbers
Challenge rate is the share of questions that pushed back, pressed for specifics or questioned management’s assumptions. It describes how questions were asked on the calls tracked here; it does not measure whether any view turned out to be right.
Rounding. Rates are rounded to whole percentages, so a small share can show as 0% even when some questions were challenging. The count beside each rate is exact; “none of N questions” means no question was challenging.
No questions recorded. “—” means there is nothing to calculate: no questions were recorded for that period on the calls tracked here. It does not mean there was no activity.
Fewer than 3 questions. A company-level rate is withheld when fewer than 3 questions were recorded for that company; the questions are still counted everywhere else.
Small samples. Profiles with fewer than 10 questions are marked Limited sample.
Reporting periods. Questions are grouped by the calendar quarter each company’s fiscal reporting period maps to, not by the date of the call. Periods without a calendar mapping are listed separately under their fiscal label.
Questions asked
Grouped by company, most questions first. Open a company to read its questions, newest reporting period first.
Showing 54 of 54 questions from 11 companies
DDDuPont11 questions · 6 reporting periods · 0 of 11 challenging
Calendar 2026 Q1
can you just talk about some of the underlying demand trends that are driving growth across the medical packaging and devices spaces
Show response
Koch attributed healthcare growth to aging population and healthcare access megatrends. Med packaging exposure skews to higher-end Class 3 devices. Spectrum focused on cardiovascular and non-elective surgery applications.
when are you assuming the conflict in the Middle East resolved, if at all?
Show response
Franzen confirmed guidance assumes Middle East conflict and current oil/gas prices persist all year. Pricing actions already in place cover that scenario. Would take further actions if situation escalates.
Calendar 2025 Q4
is it still possible to change your industry designation
Show response
Koch noted portfolio and performance clearly not a chemical company. Making progress on GICS reclassification but prioritizing execution. Continuing to push forward.
Any differences between nonres, res, and repair and model
Show response
Koch broke out: non-res up low single digits, repair & remodel up low single digits, offset by resi down low-to-mid single digits, netting to flat overall Shelter.
Calendar 2025 Q3
if it doesn't change it stays in chemicals, why do you think that is
Show response
Franzen stated unequivocally that no specialty chemical peers are comparable, pointing to multi-industrial peers as the right benchmark regardless of GICS outcome.
Calendar 2025 Q2
Can you remind us kind of where we're at in terms of how much the portfolio is in advanced nodes and how much AI will continue to drive the growth
Show response
Kemp sized advanced nodes at 35% of Semi (vs 20% industry), AI/data center at 15% of total portfolio growing above 20% in Q2.
Anything else to point out to folks as you look to maybe shift that SIC code to industrials or manufacturing versus chemicals
Show response
Franzen pointed to portfolio composition (40% Healthcare & Water), stable performance vs volatile chemicals, and continued GICS reclassification work.
Calendar 2025 Q1
how should investors think about sort of the right companies to compare you with?
Show response
Kemp positioned Qnity as a semi-industry pure-play, acknowledging short-term multiple compression at peers but citing favorable long-term dynamics.
There's a lot of cost - a lot of questions on whether we peak, whether we're continuing to grow, what we're early in the potential
Show response
Kemp emphasized very early AI adoption innings, citing hyperscaler capex increases and Qnity's 15% data center exposure growing mid-teens.
Calendar 2024 Q4
Can you remind us how big, I guess, advanced nodes are now for semi-tech and Interconnect and then maybe what the growth rate for that subset will be in '25?
Show response
Koch sized advanced nodes at ~40% of Semi portfolio with above-average growth, noting AI-specific exposure saw 30% growth.
organic growth in IndustrialsCo in the fourth quarter as well as your outlook in the first quarter, appears pretty differentiated relative to traditional chemical companies
Show response
Koch highlighted growth profile, margin superiority, and lack of commodity pricing volatility vs chemicals. Breen noted Delrin divestiture removed last chemical vestige.
DOWDow Inc.6 questions · 6 reporting periods · 1 of 6 challenging
Calendar 2026 Q1
When you think about the $1.75 billion for P&SP in 2Q, can you frame whether that is kind of a mid-cycle EBITDA or a peak EBITDA?
Show response
Carter said $0.26/lb integrated margin improvement is mid-cycle to slightly above. Impact is 3x Winter Storm Uri 2021. Expects environment to move from mid-cycle to peak levels. Recovery duration 6-18 months.
Calendar 2025 Q4
Can you help me understand how much of your ASP capacity goes to the export market?
Show response
Fitterling said 30-40% to exports; product mix differentiation matters for returns. Long-term, Americas, Middle East and Argentina will be advantaged from gas cost position.
Calendar 2025 Q3
Can you bifurcate that from whether pricing or cost in the U.S., Europe and export?
Show response
Carter explained Q4 margin compression from feedstock costs not pricing, with $0.05/lb on table for October. Fitterling said 2026 improvement needs trade deal settlement; tech/AI/data centers will continue regardless.
Calendar 2025 Q2
How do you get adjusted EBIT better? It just seems like it could be a little bit better
Show response
Carter detailed Q3 margin improvement from June exit rate, July price increases, Poly-7 fully sold out. Fitterling described Diamond Infrastructure data center opportunity with 4,000-5,000 acres for colocation.
Calendar 2025 Q1
how could EBITDA get better in the second half? I know you have some cost savings
Show response
Fitterling cited three growth projects, normalizing energy costs, $300M cost reductions for the year, and supply chain flexing advantage. Wildcard is tariff clarity on demand.
Calendar 2024 Q4
if demand is unfortunately similar in 2025 versus 2024, I mean, directionally, should EBITDA be up, down, flat?
Show response
Fitterling framed cost actions as the bridge to improved EBITDA, acknowledging pricing power is the real question rather than volume growth.
PPGPPG Industries6 questions · 6 reporting periods · 1 of 6 challenging
Calendar 2026 Q1
how do you see volumes sort of shaping up sort of at the midpoint? Any effects from the [indiscernible] conflict on each of the segments?
Show response
Knavish outlined 5 H2 volume drivers: aerospace beating expectations with improving output, refinish recovering earlier than expected with 2 positive data points (claims and distributor orders), industrial share wins launching through year, Mexico retail strong with improving projects, packaging and PMC both growing. No order book changes from Iran conflict, only feedstock pricing impact. Morales reminded that H1 2025 refinish comps create much easier H2 comparisons.
Calendar 2025 Q4
Architectural EME, you know, a business that has struggled to grow. I mean, end markets, I understand. But, you know, why is that a good business?
Show response
Knavish defended Architectural EMEA: generated record earnings and cash in 2023 (depressed market). Cash funds higher-growth businesses. Not projecting upside in 2026, assuming flat. Cost actions will drive margin and cash expansion. Morales noted COVID-era maintenance cycle pull-forward now reaching 5-year repaint window. Industrial more cyclical but seeing green shoots in Europe/LatAm share gains.
Calendar 2025 Q3
What do you think needs to happen for that business to sort of turn around maybe sometime next year?
Show response
Knavish identified France, Netherlands, U.K., and Poland as biggest markets. Consumer confidence driven by inflation, interest rates, wars, and energy. PPG taking aggressive structural cost actions, flat demand would deliver strong leverage due to 36 straight quarters of price increases. Eastern Europe recovering faster.
Calendar 2025 Q2
the only blemish looks like Refinish is down. All the other segments had a really nice year- over-year improvement. Just curious on the outlook for Refinish
Show response
Knavish noted flat Refinish performance despite high-single-digit collision claim declines. Q3 expected soft due to distributor order pattern normalization, Q4 more normalized. Industry recovery of claims likely not until 2026. On PMC: 9 straight quarters of growth, bullish for foreseeable future driven by fire protection and marine aftermarket technologies.
Calendar 2025 Q1
Volumes pretty impressive there. What do you think your volume should be for this year in total? And then what do you think market demand is?
Show response
Knavish highlighted strong demand across all Performance Coatings businesses. Morales added context on 2-year stacks: aerospace and PMC up double digits, refinish and traffic up low-to-mid single digits, with those traits expected to continue despite harder H2 comps.
Calendar 2024 Q4
Are there businesses you want to exit? Just maybe give us your thoughts on why -- what's last or what's in performance kind of Industrial Coatings
Show response
Knavish firmly stated no additional divestitures planned. Highlighted Performance Coatings 'crushed it' and Industrial at trough with significant volume leverage ahead.
SHWThe Sherwin-Williams Company6 questions · 6 reporting periods · 1 of 6 challenging
Calendar 2026 Q1
it just feels like U.S. architectural paint demand in the U.S. has been structurally impaired
Show response
Heidi pushed back on word impaired, said under pressure. Assured scenario planning includes softer for much longer. Emphasized residential repaint as largest share gain opportunity even in this environment.
Calendar 2025 Q4
what do you think would be helpful in terms of maybe sparking a recovery in paint demand this year?
Show response
Heidi framed it as three-legged stool (income, rates, affordability) and pivoted to strong AI infrastructure/data center positioning for protective and marine.
Calendar 2025 Q3
Your pricing capture this year has been better or higher than in the past. What do you think pricing capture would be in '26
Show response
Al declined to commit beyond 2026; emphasized balancing gallon growth with effectiveness; noted segment mix dilutes price/mix bucket reporting.
Calendar 2025 Q2
what mortgage rate do you think we need to get to for industry volumes to turn the corner? I mean, with six percent help, five percent
Show response
Heidi characterized sub-6% as meaningful trigger but equally cited consumer confidence and affordability. Jim noted Q2 new res up slightly vs double-digit completions declines as evidence of share gains.
Calendar 2025 Q1
price mix for the stores, up mid-single-digits. Was that mostly price or if it's maybe half-half with mix, what is that mix component to that equation?
Show response
Al said mid-single-digit price mix was predominantly price with better effectiveness than last year; res repaint growth contributes positive mix shift vs commercial and property maintenance.
Calendar 2024 Q4
in 24, you generated pretty good APS growth of 10%. So if you think about '25
Show response
Al walked through higher interest expense (refinancing at higher rates), new building financing, non-operating normalization, and ex-new-building midpoint of $12.15/~7% growth. Heidi added single-family starts and multi-family completions as persistent headwinds.
APDAir Products5 questions · 5 reporting periods · 1 of 5 challenging
Calendar 2026 Q1
There's a relatively sizable IPO coming at the summer in space. Just curious if you could give us your thoughts on your business in that sector
Show response
Eduardo noted fast-growing segment with long NASA history since the 1960s. Working to increase share with commercial launches but declined specific financial details.
Calendar 2025 Q3
If you get to partners for sequestration pneumonia who want a similar return that you would want, is there still a good return on the hydrogen
Show response
Eduardo confirmed APD viewing Louisiana as a standard hydrogen project that must meet normal return criteria for both sides. Believes room exists to reach right returns but capital cost estimate is key variable.
Calendar 2025 Q2
Have any update there? I haven't seen any announcements. How is bidding activity going with that?
Show response
Eduardo noted strong pipeline of small projects and large electronics investments in Asia (Taiwan, China, Korea). Plans to summarize annual investment activity next quarter.
Calendar 2025 Q1
you think the $5 billion, would generate around a 5% or mid-single-digit return
Show response
Eduardo acknowledged the simplified math implies depreciation-only returns but wouldn't confirm specific hurdle rates for competitive reasons.
Calendar 2024 Q3
do you think at some point for the clean hydrogen projects that demand will be big enough? When you announce a project, you'll have offtakes immediately?
Show response
Seifi committed to future projects requiring 50-60% offtake before announcement, modeling the traditional on-site business model.
IFFInternational Flavors & Fragrances5 questions · 5 reporting periods · 2 of 5 challenging
Calendar 2026 Q1
At what point does this inflation flow through to the consumer and start to impact demand?
Show response
Erik expects continued solid demand. Fine Fragrance growth to moderate from double-digit but remain positive full year, with temporary Middle East import slowdown. Consumer Fragrance pipeline growing. Only commodity ingredients (~half of Fragrance Ingredient sales) remain challenged.
Calendar 2025 Q4
historically, International Flavors & Fragrances Inc. has slightly underperformed to F&F peers, but if you think about the portfolio going forward, the Health and Biosciences and Scent and Taste, h...
Show response
Erik argued focused portfolio of Taste, Scent, H&B will accelerate growth through concentrated R&D investment and biotechnology cross-pollination. Cited EnviroCAPS and Super Carrot as examples of biotech-driven innovation across segments.
Calendar 2025 Q2
If you take out pharma from your first half EBITDA, it's somewhere around $1050 million. Your outlook for the second half implies mid-900s at the midpoint. It's about down 10% sequentially
Show response
DeVeau attributed sequential EBITDA decline to normal Q4 seasonality (lowest margin quarter at ~17% last year vs 20%+ in H1) plus modest volume softening, though acknowledged he didn't have precise like-for-like comparison data available.
Calendar 2025 Q1
EBITDA margins first quarter were very good. And you guys talked about net pricing and productivity was noted for the year of increase. How much did each contribute
Show response
Erik attributed gains to productivity and mix improvement toward higher-margin products. Committed to above 15% EBITDA margin through 2026.
Calendar 2024 Q4
where do you think International Flavors & Fragrances Inc.'s EBITDA should get over time
Show response
Erik directly addressed long-term EBITDA margin target of low 20s and acknowledged food ingredients as the biggest challenge while expressing confidence in HNB, scent, and taste.
Show 5 more companies
LINLinde plc5 questions · 3 reporting periods · 3 of 5 challenging
Calendar 2026 Q1
it's going to be what the third or fourth year of no economic improvement for industrial demand. I can't imagine the Iran conflict is going to help that
Show response
White said stability needed for large durable goods and infrastructure projects requiring financing and long-range returns. IAA in Europe is a catalyst example. Americas showing positive signs from protectionist policies. APAC stable with China steady, India growing.
Chemicals and Energy, sales were up 3% in the first quarter on Slide 3. What do you think the run rate of that is heading into the 2Q
Show response
White said Americas-led chemicals and energy strength expected to continue. Comps getting easier as they lap years of stagnant conditions. Remains positive on the outlook through the year.
Calendar 2025 Q3
you had commented that you saw the cycle will turn positive. We've seen a lot of companies this quarter have asset write-downs
Show response
Sanjiv acknowledged chemicals most impacted currently. Cited European capacity rationalization as eventually supporting recovery. China chemicals still reasonable. Not suggesting imminent recovery but expects cycle to turn based on historical patterns.
SG&A was up 9% year-over-year, sequential up 3%. Any particularly -- any reason for that trend?
Show response
Sanjiv said quarterly SG&A has timing noise. Year-to-date SG&A up only 1%: M&A added ~1%, inflation ~2%, offset by restructuring savings of ~2%. Prefers YTD view over quarterly.
Calendar 2025 Q2
The recent agreement, it's a merchant contract, as I recall. So when do you think these will convert into an on-site?
Show response
Sanjiv said space revenue quadrupled in 3 years. Supplies 4 out of 5 US launches. Investing ~$1B over next few years. Strong long-term customer commitments even if not classified as backlog.
LYBLyondellBasell4 questions · 4 reporting periods · 0 of 4 challenging
Calendar 2026 Q1
can that product line turn positive? And you used to generate a good amount of EBITDA for polypropylene
Show response
Peter emphasized PP as biggest upside opportunity. Market dynamics completely changed with US now seeing global demand for PP exports that normally stayed in production region. Kim noted PP operated at 70-75% for 2 years in Europe and US, meaning 15-20% operating rate improvement opportunity plus spread expansion. The longer the conflict persists, the better for PP.
Calendar 2025 Q4
how much of that capacity do you export
Show response
Peter noted LYB has historically lower exports due to more differentiated domestic portfolio. Kim quantified: LYB exported 34% and 38% in 2024/2025 vs industry ~48%. 2025 was difficult year for export pricing due to tariff-driven supply chain disruption. Expects 2026 normalization as tariffs and supply chains stabilize, improving netbacks across regions.
Calendar 2025 Q2
Do you think earnings could be up or down or just general direction given everything that you see now? And then longer term, I guess, mid-cycle potential for EBITDA, has it changed
Show response
Peter walked through segments: O&P Americas benefits from $85M less downtime plus improved PE margins and fixed cost reductions. Europe sees improved polymer margins with favorable naphtha and higher operating rates after Wesseling outage resolved. I&D expected flat. APS and Technology flat. Noted consumer behavior shifting toward more at-home consumption supporting packaging demand.
Calendar 2025 Q1
what trough EBITDA should be per se
Show response
Peter noted underlying Q1 EBITDA was ~$100M higher than Q4 when adjusting for $200M turnaround/weather impacts. Difficult to predict cycle bottom. Expects eventual durable goods replenishment but timing uncertain. Declined to give a specific trough number.
CFCF Industries3 questions · 2 reporting periods · 1 of 3 challenging
Calendar 2026 Q1
how tight do you think it will be? Do you think nitrogen and prevailing products will stay above the average, and how should we think about the longevity of this elevated pricing?
Show response
Chris outlined extended recovery timeline: 30-40 day normal transport plus restart delays, vessel quality issues, inflation in risk premiums and insurance. Argued mid-cycle urea costs increase structurally. Bert compared disruption to running like a Ferrari now disrupted, with stocks-to-use ratios tight and Bangladesh, India, Pakistan facing suboptimal operations due to LNG dependency. Both expect pricing above average through 2027.
Calendar 2025 Q4
if it goes away, does that make it difficult or maybe impossible to get a premium price for Blue Point?
Show response
Chris argued CBAM removal would not eliminate premium opportunity due to broader ETS free allowance phase-out and growing global demand for low-carbon products. Bert confirmed contracts in place for 2026 with demand for more, seeing interest from industrial and agricultural customers globally beyond European regulation.
Is your bias that pricing kind of stays at this level and maybe the biases may be potentially to go up from here?
Show response
Bert said still room for prices to rise in North America but expects a correction in the back half as demand shifts from Northern to Southern Hemisphere planting. Cited 3-4 months of actual application demand in North America requiring 6-7 months of inventory build creating structural timing dynamics.
MOSMosaic Company (The)2 questions · 2 reporting periods · 0 of 2 challenging
Calendar 2026 Q1
If the 2Q volumes come in as is, is that the base case for the third quarter
Show response
Bodine declined to confirm Q2 as Q3 base, citing scenarios ranging from rapid Persian Gulf resolution improving things within 60 days to protracted conflict requiring further curtailments. Sulfur availability, both price and physical access, is the key variable. Management cannot predict conflict resolution timeline. Additional curtailment options are being evaluated if needed.
Calendar 2025 Q4
If on Slide 14, the February '26 metrics don't change, is that a similar headwind for the rest of the quarters
Show response
Bodine noted sulfur headwind would persist if prices stay elevated but ammonia expected to decline through 2026. Improved turnaround costs and fixed cost absorption from higher production provide buffers. Luciano provided detailed breakeven math: Q4 realized $444/ton stripping margin, $108 EBITDA margin, normalized breakeven approximately $250/ton at full production. At $400 stripping margin, approximately $150/ton EBITDA achievable.
CTVACorteva1 question · 1 reporting period · 0 of 1 challenging
Calendar 2025 Q4
Anything in particular that gives you confidence there?
Show response
Robert said expecting modest global CP market growth in 2026, volume-driven with some pricing headwinds. Northern Hemisphere order books strong. Brazil has ample generic supply keeping pressure on pricing but differentiated products still in demand with 10-15% margin premium.
Challenge rate by company
Every company this analyst questioned, most questions first. A company-level rate is shown from 3 questions; below that it is withheld.
| Company | Questions | Challenge rate |
|---|---|---|
| DD DuPont | 11 | 0%none of 11 questions |
| DOW Dow Inc. | 6 | 17%1 of 6 questions |
| PPG PPG Industries | 6 | 17%1 of 6 questions |
| SHW The Sherwin-Williams Company | 6 | 17%1 of 6 questions |
| APD Air Products | 5 | 20%1 of 5 questions |
| IFF International Flavors & Fragrances | 5 | 40%2 of 5 questions |
| LIN Linde plc | 5 | 60%3 of 5 questions |
| LYB LyondellBasell | 4 | 0%none of 4 questions |
| CF CF Industries | 3 | 33%1 of 3 questions |
| MOS Mosaic Company (The) | 2 | —Rate withheld: fewer than 3 questions |
- DDDuPont · 11 questions0%none of 11 questions
- DOWDow Inc. · 6 questions17%1 of 6 questions
- PPGPPG Industries · 6 questions17%1 of 6 questions
- SHWThe Sherwin-Williams Company · 6 questions17%1 of 6 questions
- APDAir Products · 5 questions20%1 of 5 questions
- IFFInternational Flavors & Fragrances · 5 questions40%2 of 5 questions
- LINLinde plc · 5 questions60%3 of 5 questions
- LYBLyondellBasell · 4 questions0%none of 4 questions
- CFCF Industries · 3 questions33%1 of 3 questions
- MOSMosaic Company (The) · 2 questions—rate withheld: under 3 questions
Activity by reporting period
Questions recorded for each calendar quarter that companies’ reporting periods map to (not the call date), with the challenge rate for that period. Periods inside the range with no questions are shown as “No questions recorded”.
| Calendar period | Questions | Challenge rate | Companies |
|---|---|---|---|
| 2024 Q3 | 1 | 0%none of 1 question | 1 |
| 2024 Q4 | 6 | 17%1 of 6 questions | 5 |
| 2025 Q1 | 8 | 13%1 of 8 questions | 7 |
| 2025 Q2 | 9 | 11%1 of 9 questions | 8 |
| 2025 Q3 | 7 | 29%2 of 7 questions | 6 |
| 2025 Q4 | 11 | 27%3 of 11 questions | 9 |
| 2026 Q1 | 12 | 17%2 of 12 questions | 10 |
- 2024 Q31 question · challenge rate 0% (none of 1 question) · 1 company
- 2024 Q46 questions · challenge rate 17% (1 of 6 questions) · 5 companies
- 2025 Q18 questions · challenge rate 13% (1 of 8 questions) · 7 companies
- 2025 Q29 questions · challenge rate 11% (1 of 9 questions) · 8 companies
- 2025 Q37 questions · challenge rate 29% (2 of 7 questions) · 6 companies
- 2025 Q411 questions · challenge rate 27% (3 of 11 questions) · 9 companies
- 2026 Q112 questions · challenge rate 17% (2 of 12 questions) · 10 companies
Topics
Topics tagged on this analyst’s questions.
- Demand27
- Competitive Dynamics14
- Margin14
- Pricing10
- Macroeconomic9
- Revenue Growth6
- Capex Investment6
- Cost Pressure5
- Cloud & AI3
- M&A3
Show all 14 topics
- Supply Chain2
- Regulation Policy2
- Innovation & R&D1
- Capital Allocation1